RX.V - BioSyent Inc.
| Previous Close | 3.6200 |
| Open | 3.7000 |
| Bid | 3.6400 x 0 |
| Ask | 3.7200 x 0 |
| Day's Range | 3.6400 - 3.7200 |
| 52 Week Range | 3.1300 - 8.3400 |
| Volume | 36,299 |
| Avg. Volume | 14,107 |
| Market Cap | 48.509M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 11.94 |
| EPS (TTM) | 0.3100 |
| Earnings Date | Mar. 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- GlobeNewswire
BIOSYENT ANNOUNCES GRANT OF RESTRICTED SHARE UNITS
BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved today a grant of 129,125 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.
- Simply Wall St.
Seyed Ashrafi Just Bought Shares In BioSyent Inc. (CVE:RX)
Even if it's not a huge purchase, we think it was good to see that Seyed Ashrafi, a BioSyent Inc. (CVE:RX) insider...
- Simply Wall St.
BioSyent Inc. (CVE:RX) Just Reported And Analysts Have Been Cutting Their Estimates
BioSyent Inc. (CVE:RX) shareholders are probably feeling a little disappointed, since its shares fell 4.5% to CA$3.58...
- GlobeNewswire
BioSyent Releases Results for Fourth Quarter and Full Year 2019
MISSISSAUGA, Ontario, March 18, 2020 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended.
- GlobeNewswire
BIOSYENT SCHEDULES Q4 AND FULL YEAR 2019 EARNINGS RELEASE FOR MARCH 18, 2020
MISSISSAUGA, Ontario, March 11, 2020 -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and twelve months ended.
- Simply Wall St.
What Is BioSyent's (CVE:RX) P/E Ratio After Its Share Price Tanked?
Unfortunately for some shareholders, the BioSyent (CVE:RX) share price has dived 33% in the last thirty days. That...
- GlobeNewswire
BioSyent Announces Adoption of Restricted Share Unit Plan
BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a Restricted Share Unit Plan (the “RSU Plan”). The RSU Plan is established as a vehicle by which equity-based incentives may be granted to eligible employees, consultants, directors and officers of the Company. The fixed maximum number of the Company’s common shares (the “Common Shares”) which may be available for issuance upon settlement of the restricted share units (the “RSUs”) issued under the RSU Plan is 800,000 Common Shares.
- Simply Wall St.
Here's How P/E Ratios Can Help Us Understand BioSyent Inc. (CVE:RX)
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at BioSyent...
- Thomson Reuters StreetEvents
Edited Transcript of RX.V earnings conference call or presentation 20-Nov-19 10:59am GMT
Q3 2019 Biosyent Inc Earnings Call
- GlobeNewswire
BioSyent Announces Renewal of Normal Course Issuer Bid
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase for cancellation up to 800,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.89% of the Shares outstanding as of December 11, 2019.
- Simply Wall St.
Should You Be Impressed By BioSyent Inc.'s (CVE:RX) ROE?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- GlobeNewswire
BioSyent Signs Exclusive Agreement for Pain Management Products
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive License and Supply Agreement (“the Agreement”) with AFT Pharmaceuticals (“AFT”, NSX: AFT, ASX: AFP) for a portfolio of new pain management products for the Canadian market. Health Canada has recently approved the first form of Combogesic® and BioSyent Pharma Inc. intends to launch the product in 2020. Under the Agreement, BioSyent Pharma Inc. also has rights to additional forms of Combogesic® - some of which have been approved in other countries and for which it intends to seek approval in Canada.
- GlobeNewswire
BioSyent Releases Results for Third Quarter and First Nine Months of 2019
MISSISSAUGA, Ontario, Nov. 20, 2019 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended.
- GlobeNewswire
BioSyent Schedules Q3 and YTD 2019 Earnings Release for November 20, 2019
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2019 on Wednesday, November 20, 2019. A presentation on the Company’s third quarter and year-to-date 2019 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.
- Simply Wall St.
Should You Worry About BioSyent Inc.'s (CVE:RX) CEO Pay?
René Goehrum became the CEO of BioSyent Inc. (CVE:RX) in 1999. First, this article will compare CEO compensation with...
- Thomson Reuters StreetEvents
Edited Transcript of RX.V earnings conference call or presentation 23-Aug-19 10:59am GMT
Q2 2019 Biosyent Inc Earnings Call
- Simply Wall St.
Should You Be Worried About Insider Transactions At BioSyent Inc. (CVE:RX)?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Seventh Consecutive Year
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been named to the 31st annual Growth 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s. The Growth 500 ranks Canada’s top private and public companies based on five-year revenue growth. Based on a five-year revenue growth rate of 176% (2013 - 2018), BioSyent was named as one of Canada’s Fastest-Growing Companies on the 2019 Growth 500 list. This is the seventh consecutive year that BioSyent has been named to the Growth 500 list – formerly known as the PROFIT 500.
- GlobeNewswire
BioSyent Releases Q2 and H1 2019 Results
MISSISSAUGA, Ontario, Aug. 23, 2019 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30,.
- Simply Wall St.
The BioSyent (CVE:RX) Share Price Is Down 34% So Some Shareholders Are Getting Worried
Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...
- GlobeNewswire
BioSyent Schedules Q2 and H1 2019 Earnings Release for August 23, 2019
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2019 on Friday, August 23, 2019. A presentation on the Company’s second quarter and first half 2019 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
- The Motley Fool
Find Fortune in These 2 Strong Small Caps
Having trouble finding value in the stock market? Consider fundamentally strong small-cap stocks such as Biosyent Inc. (TSXV:RX) and Tidewater Midstream & Infrastructure Ltd. (TSX:TWM).
- Simply Wall St.
Despite Its High P/E Ratio, Is BioSyent Inc. (CVE:RX) Still Undervalued?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...
- Simply Wall St.
An Intrinsic Calculation For BioSyent Inc. (CVE:RX) Suggests It's 49% Undervalued
How far off is BioSyent Inc. (CVE:RX) from its intrinsic value? Using the most recent financial data, we'll take a...
- The Motley Fool
3 Traits of the Best Stocks
Here’s why Biosyent Inc. (TSXV:RX) stock is a great bet for massive upside from current levels.
